International Journal of Hematology

, 76:436

Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia

Authors

    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Nobuaki Dobashi
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Osamu Asai
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Shingo Yano
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Yuichi Yahagi
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Takeshi Saito
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Yuko Yamaguchi
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Kinuyo Kasama
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Yutaka Okawa
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Naohiro Sekiguchi
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Yutaka Takei
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Katsuki Sugiyama
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Yoji Ogasawara
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Hiroko Ohtsubo
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Ken Kaito
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
  • Masayuki Kobayashi
    • Division of Hematology and Oncology, Department of Internal MedicineThe Jikei University School of Medicine
Progress in hematology

DOI: 10.1007/BF02982809

Cite this article as:
Usui, N., Dobashi, N., Asai, O. et al. Int J Hematol (2002) 76: 436. doi:10.1007/BF02982809

Abstract

To investigate whether an intensified dose of daunorubicin (DNR) in induction therapy and autologous peripheral blood stem cell transplantation (PBSCT) in the postremission period are effective treatments, we used a Double-7 protocol to treat adult patients with de novo acute myeloid leukemia (excluding M0 and M3). Induction therapy consisted of 40 mg/m2 of DNR intravenous drip infusion for 7 days and 200 mg/m2 of ara-C by continuous infusion for 7 days (7 + 7 DC regimen). Patients who achieved complete remission (CR) were given high-dose chemotherapy with autologous PBSCT in postremission therapy. Of the 22 assessable patients, 16 attained CR (73%). Disease-free survival (DFS) and overall survival (OS) at 3 years were 61.2% and 48.1%, respectively. Nine of the CR patients underwent PBSCT without therapy-related mortality. Patients in a favorable cytogenetic group (n = 7) attained 100% CR and long-term survival (71.4% DFS and 85.7% OS at 3 years). Thus, intensified DNR administration of 280 mg/m2 (40 mg/m2 per day for 7 days) in induction therapy for adult patients younger than 60 years of age might be optimal or at least comparable with the new anthracyclines such as idarubicin. In addition, autologous PBSCT in postremission therapy might improve DFS and OS, at least for patients in a favorable cytogenetic group, such as those with a t(8;21) abnormality.Int J Hematol. 2002; 76: 436-445.

Key words

Adult AMLDaunorubicinInduction therapyAuto-PBSCTDouble-7

Copyright information

© The Japanese Society of Hematology 2002